A couple of years ago, the Danish pharmaceuticals Novo Nordisk turned the pharmaceutical market. Your drug against diabetes, Ozempicbegan its route outside its initial market niche, transforming (with the name of Wegovy) into a drug for weight reduction.
Change of strategy. Years later, in an increasingly competitive market, the European company has introduced news in its strategy of marketing in the United States. He has done it with a new direct marketing system to patients without insurance from the Wegovy drug and patients whose coverage does not cover treatment.
The pharmacist has indicated that the new sales system will be at home. In treatment, it will be priced at $ 499 per month, to pay in cash. This price is remarkably lower than paying today who want to buy the drug in the United States without the protection of its insurer, about $ 1,350.
According to the pharmaceutical, insured persons must pay a cost is between zero and $ 25 per month for Wegovy. About 90% of people who use this treatment in the US do so in these conditions. The new strategy change could alter this ratio.
Wegovy Wegovy is one of the names with which the company Novo Nordisk markets its semaglutida drugs, the compound behind Ozempic. Both Ozempic and Wegovy work by releasing this analogue of GLP-1 hormones in our body (peptide similar to type 1 glucagon).
The GLP-1 hormone is secreted when we consume food and fulfill several functions in our body. On the one hand, he warns the pancreas that he must begin to produce insulin, hence its usefulness for people with diabetes. On the other, it sends to our brain the message that we have satiated, which in turn could be behind the weight loss with which this drug is associated.
Novocare Pharmacy. The company He has baptized This initiative as Novocare Pharmacy. The shipments will be made through the Centerwell Pharmacy company, so the company will not dispense with intermediaries in its new strategy.
The company emphasizes that people with medical prescription for Wegovy will be able to access this service that will take the treatment to their homes. This, they continue to explain, will allow a better product verification, reminders for the “filled” and access to a manager of your own case.
An increasing competition. The Wegovy market niche is an increasingly disputed. After The entrance Of the American pharmaceutical Lilly with new formulas, the domain of Ozempic and Wegovy has been restricted. Supply problems seen in recent months have also modulated a market in which many pharmaceuticals want to enter.
Image | Chemist4u